Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
作者： Anastasia-Stefania Alexopoulos , Ali Qamar , Kathryn Hutchins , Matthew J. Crowley , Bryan C. Batch
DOI: 10.1007/S11892-019-1136-3
关键词:
摘要: … ), and EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People … ) which will be investigating the effects of Icosapent ethyl (Vascepa), 4 g daily, on coronary …
springer.com
sci-hub.se 参考文章(88)
ORIGIN Trial Investigators, None, n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. The New England Journal of Medicine. ,vol. 367, pp. 309- 318 ,(2012) , 10.1056/NEJMOA1203859
Terry Jacobson, None, National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 Journal of Clinical Lipidology. ,vol. 9, pp. S1- S122.e1 ,(2015) , 10.1016/J.JACL.2015.09.002
, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients New England Journal of Medicine. ,vol. 371, pp. 203- 212 ,(2014) , 10.1056/NEJMOA1300955
Yue-hong Chen, Liang Du, Xing-yuan Geng, Yuan-ling Peng, Jia-ni Shen, Yong-gang Zhang, Guan-jian Liu, Xin Sun, Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials Journal of Evidence-Based Medicine. ,vol. 8, pp. 134- 148 ,(2015) , 10.1111/JEBM.12157
R. Scott, R. O'Brien, G. Fulcher, C. Pardy, M. d'Emden, D. Tse, M.-R. Taskinen, C. Ehnholm, A. Keech, , Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. ,vol. 32, pp. 493- 498 ,(2009) , 10.2337/DC08-1543
Nadeem Sarwar, John Danesh, Gudny Eiriksdottir, Gunnar Sigurdsson, Nick Wareham, Sheila Bingham, S. Matthijs Boekholdt, Kay-Tee Khaw, Vilmundur Gudnason, Triglycerides and the Risk of Coronary Heart Disease 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies Circulation. ,vol. 115, pp. 450- 458 ,(2007) , 10.1161/CIRCULATIONAHA.106.637793
Robert S Rosenson, Current overview of statin-induced myopathy. The American Journal of Medicine. ,vol. 116, pp. 408- 416 ,(2004) , 10.1016/J.AMJMED.2003.10.033
Fernando Ovalle, Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clinical Therapeutics. ,vol. 33, pp. 393- 407 ,(2011) , 10.1016/J.CLINTHERA.2011.04.006
Manfredi Rizzo, Ali A Rizvi, Giatgen A Spinas, Giovam Battista Rini, Kaspar Berneis, Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opinion on Investigational Drugs. ,vol. 18, pp. 1495- 1503 ,(2009) , 10.1517/14728220903241633
Gerald F. Watts, Esther M. M. Ooi, Dick C. Chan, Demystifying the management of hypertriglyceridaemia Nature Reviews Cardiology. ,vol. 10, pp. 648- 661 ,(2013) , 10.1038/NRCARDIO.2013.140